Business description: AB Science

AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Number of employees: 31

Sales by Activity: AB Science

Fiscal Period: December 2021 (EUR) 2022 (EUR) 2023 (EUR) 2024 (EUR) 2025 (EUR)

Pharmaceuticals

1.61M 958K 970K 1.07M 1.17M

Geographical breakdown of sales: AB Science

Fiscal Period: December 2021 (EUR) 2022 (EUR) 2023 (EUR) 2024 (EUR) 2025 (EUR)

Europe

- - - - 955K

outside Europe

- - - - 219K

Executive Committee: AB Science

Manager TitleAgeSince
Chief Executive Officer - 07/07/2026
Director of Finance/CFO - 20/11/2009
Chief Tech/Sci/R&D Officer - 01/04/2018
Corporate Officer/Principal - -

Composition of the Board of Directors: AB Science

Director TitleAgeSince
Chairman - 11/07/2001
Director/Board Member - 20/09/2011
Director/Board Member 64 27/06/2021
Director/Board Member 68 27/06/2021
Director/Board Member - 27/06/2021
Chairman - 07/07/2026

Shareholders: AB Science

NameStocks%Valuation
UBS Wealth Management SGIIC SA
0.004443 %
3,100 0.004443 % 3 137 €
NameStocks%Valuation
Friedland Gestion SAS
5.198 %
85,471 5.198 % 32 638 €
NameStocks%Valuation
Friedland Gestion SAS
4.167 %
64,103 4.167 % 20 081 €

Company details: AB Science

AB Science SA

3, avenue George V

75008, Paris

+33 1 47 20 00 14

http://www.ab-science.com
address AB Science(AB)

Specialty & Advanced Pharmaceuticals

Change 5-day change 1-year change 3-year change Capi.($)
-4.67%+1.34%-64.31%-86.24% 50.72M
-0.44%-0.53%+58.76%+22.05% 322B
-1.55%+2.59%+28.35%-10.91% 71.8B
+0.02%+3.04%+38.65%+90.79% 9.88B
-2.81%-1.62%-0.83%-5.17% 8.64B
+2.65%+1.04%-23.09%-5.02% 4.08B
+5.26%+5.41%-38.54%+12.12% 3.61B
-3.86%-8.18%-12.14%-2.26% 3.61B
-2.06%-3.35%+35.91%+49.93% 2.7B
-0.68%+4.52%-4.75%-5.33% 2.24B
Average -0.81%+1.81%+1.80%+6.00% 42.86B
Weighted average by Cap. -0.63%+4.47%+49.32%+17.04%